Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb;39(2):428-33.
doi: 10.1016/j.addbeh.2013.08.014. Epub 2013 Aug 22.

Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress

Mehmet Sofuoglu  1 , Robert Rosenheck, Ismene Petrakis
Affiliations
Review

Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress

Mehmet Sofuoglu et al. Addict Behav. 2014 Feb.

Abstract

Previous research has identified a strong association between posttraumatic stress disorder (PTSD) and substance use disorder (SUD), necessitating the development of treatments that address both conditions. Some pharmacotherapies are effective for the treatment of PTSD and SUD alone, however; no medications have been proven to be effective for the combination of these conditions. We review the recent advances in pharmacological treatment of comorbid PTSD and SUD. A randomized clinical trial of sertraline, a serotonin reuptake inhibitor (SSRI), did not show overall efficacy for comorbid PTSD and alcohol dependence (AD), although it may have efficacy among light drinkers. Another clinical trial demonstrated the efficacy of both disulfiram and naltrexone for the treatment of AD in individuals with PTSD. A more recent clinical trial suggested that norepinephrine uptake inhibitors may also have efficacy for the treatment of comorbid PTSD and AD. In animal and preliminary human studies, brain norepinephrine and glutamate/GABA have emerged as potential treatment targets for comorbid PTSD and SUD. Noradrenergic medications that are promising for comorbid PTSD and SUD include prazosin, guanfacine, and atomoxetine. Promising glutamate/GABA medications include topiramate, memantine, acamprosate, N-acetylcysteine (NAC), and ketamine. The safety and efficacy of these medications for the treatment of PTSD and SUD need to be tested in controlled clinical trials.

Keywords: Alcohol dependence; Comorbidity; PTSD; Pharmacotherapy; Substance use disorder.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: MS serves as an expert witness on behalf of Pfizer in lawsuits related to varenicline. Other authors declare that they have no conflicts of interest.

References

    1. Alderman CP, McCarthy LC, Condon JT, Marwood AC, Fuller JR. Topiramate in combat-related posttraumatic stress disorder. Ann Pharmacother. 2009;43(4):635–641. - PubMed
    1. Arnsten AF. Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry. 2011;69(12):e89–99. - PMC - PubMed
    1. Baker DA, McFarland K, Lake RW, Shen H, Toda S, Kalivas PW. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Annals of the New York Academy of Sciences. 2003;1003:349–351. - PubMed
    1. Battista MA, Hierholzer R, Khouzam HR, Barlow A, O’Toole S. Pilot trial of memantine in the treatment of posttraumatic stress disorder. Psychiatry. 2007;70(2):167–174. - PubMed
    1. Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Malhi GS. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. Journal of Affective Disorders. 2011;135(1–3):389–394. - PubMed

Publication types

MeSH terms